ArticleScientific reports2025
UPLC-Q-TOF/MS, network pharmacology, molecular docking, and experimental validation to explore the mechanisms of toad clothing on rheumatoid arthritis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Toad clothing (toad slough) detoxifies, reduces oedema and analgesia, is anti-inflammatory and anti-tumour, and regulates the immune system. Toad clothing's mechanism is unclear. The molecular mechanism of toad clothing in rheumatoid arthritis (RA) therapy will be investigated in this research. We used Ultra-Performance Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometry (UPLC-Q-TOF/MS), network pharmacology, molecular docking, and in vitro experiments to investigate the mechanism behind the anti-RA action of toad apparel. First, UPLC-Q-TOF/MS revealed 24 toad clothing ingredients. Network pharmacology predicted five key elements, six core targets, and the Phosphatidylinositol 3-Kinase/ Protein Kinase B (PI3K/AKT) signalling pathway. Then, molecular docking was used to validate the binding ability of core chemical constituents and core targets of toad clothing. The results showed that the primary constituent, resibufogenin, was bound tightly to six core targets and had a good affinity for key RA targets such as Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), Epidermal Growth Factor Receptor (EGFR), and Janus Kinase 2 (JAK2). Cellular tests demonstrated that resibufogenin dramatically lowered Tumour Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6), and Interleukin-1 beta (IL-1β) levels and regulated the PI3K/AKT signalling pathway. This research showed toad clothing's anti-RA pharmacodynamic material basis and mechanism, offering a theoretical foundation for its creation, use, and clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.